Sorry, you need to enable JavaScript to visit this website.
Pfizer strives to become the leading biotherapeutics company by building on internal expertise and fostering strategic partnerships to access the best technologies with patent protection and technical capabilities that provide a competitive advantage.

WRD is interested in establishing alliances to develop and access:

  • Transformational technologies to design, construct, and optimize biotherapeutics
    • nformed protein design optimizes molecular properties resulting in superior efficacy, pharmacokinetics, pharmacodynamics, safety, manufacturability and differentions
  • Antibody drug conjugate technologies
    • Novel ADC platforms, novel payloads, linkers, conjugation sites
  • Bioconjugation technologies
    • Novel approaches that enhance antibody function or improve site-specific bioconjugation
  • Combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties
  • Structure-based and computational design of therapeutics
    • Novel technologies to rationally design antibody, protein and peptide therapeutics that display superior pharmaceutical properties (including selectivity, half-life extension, stability, formulatability)
  • Technologies that enhance multi-transmembrane protein target expression/presentation for antibody generation and screening
  • Technologies and patient sample access for antibody discovery from human antibody responses
  • Targeted delivery technologies that address/ overcome cell membrane penetration, cross blood brain barrier
  • Technologies that can significantly enhance general protein expression, purification, stability for discovery
  • Integrated service providers to support early discovery activities for development of therapeutics
  • Broadly applicable platforms to enhance speed/ quality of antibody generation
  • Novel biologics, combination therapies, and "biobetters" that fit Pfizer strategies

Not actively seeking partnering opportunities in:

  • PEGylation for bioconjugation
  • Protein scaffold platforms with challenging stability attributes and/or difficult manufacturability